dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Lopez-Bonet, Eugeni |
dc.contributor.author | Buxó, Maria |
dc.contributor.author | Cuyàs, Elisabet |
dc.contributor.author | Pernas, Sonia |
dc.contributor.author | Dorca, Joan |
dc.contributor.author | Álvarez, Isabel |
dc.contributor.author | Cortés Castan, Javier |
dc.date.accessioned | 2021-04-13T14:08:29Z |
dc.date.available | 2021-04-13T14:08:29Z |
dc.date.issued | 2019-12-11 |
dc.identifier.citation | Lopez-Bonet E, Buxó M, Cuyàs E, Pernas S, Dorca J, Álvarez I, et al. Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer. J Clin Med. 2019 Dec 11;8(12):2180. |
dc.identifier.issn | 2077-0383 |
dc.identifier.uri | https://hdl.handle.net/11351/5846 |
dc.description | Metformina; Ki67; Cáncer de mama |
dc.language.iso | eng |
dc.publisher | MDPI |
dc.relation.ispartofseries | Journal of Clinical Medicine;8(12) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Metformina |
dc.subject | Mama - Càncer |
dc.subject.mesh | Breast Neoplasms |
dc.subject.mesh | /drug therapy |
dc.title | Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.3390/jcm8122180 |
dc.subject.decs | neoplasias de la mama |
dc.subject.decs | /farmacoterapia |
dc.relation.publishversion | https://www.mdpi.com/2077-0383/8/12/2180 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Lopez-Bonet E] Department of Anatomical Pathology, Dr. Josep Trueta Hospital of Girona, Girona 17005, Spain. [Buxó M] Girona Biomedical Research Institute (IDIBGI), Girona 17190, Spain. [Cuyàs E] Girona Biomedical Research Institute (IDIBGI), Girona 17190, Spain. Program Against Cancer Therapeutic Resistance (ProCURE), Metabolism and Cancer Group, Catalan Institute of Oncology, Girona 08908, Spain. [Pernas S] Department of Medical Oncology, Breast Unit, Catalan Institute of Oncology-Hospital Universitari de Bellvitge-Bellvitge Research Institute (IDIBELL), L’Hospitalet de Llobregat, Barcelona 08908, Spain. [Dorca J] Medical Oncology, Catalan Institute of Oncology, Girona 17005, Spain. [Álvarez I] Medical Oncology Service, Hospital Universitario Donostia, Donostia-San Sebastián 20014, Spain. Biodonostia Health Research Institute, Donostia-San Sebastián 20014, Spain. [Cortés J] IOB Institute of Oncology, Hospital Quirónsalud, Madrid & Barcelona 08023, Spain. Medica Scientia Innovation Researcher (MedSIR), Barcelona 08007, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain |
dc.identifier.pmid | 31835708 |
dc.identifier.wos | 000506640400150 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2013-2016/SAF2016-80639-P |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |